A “mutation-agnostic” CRISPR gene therapy approach aimed at scaling inherited rare-disease treatment is moving toward clinical use. Fyodor Urnov, director for therapeutic R&D at the Innovative Genomes Institute at UC Berkeley, framed the challenge as regulatory and operational: filing an IND/CTA for each mutation in each newborn is not sustainable. The concept is to group children by clinical syndrome and treat them with a shared editing strategy, reducing per-mutation customization. The report also underscores that umbrellaing patients into broader clinical categories could change how gene-editing programs are planned and reviewed. For the field, the push is not just technical—platformization and regulatory acceptance are now central to execution timelines for genome medicine.